Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

NCT03454750 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer
68Ga-PSMA PET/CT Positive

Interventions

DRUG: 177Lu-PSMA

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS